Clinical trials: Dementia Alzheimer Type
- Condition Dementia Alzheimer Type
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Agitation
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.
- Trial name
- NCT06052254
- Testing
- 12 cm2 - 2 Active DMTS Patches
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- Teikoku Pharma USA, Inc.
COVID-19
A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
This study is a randomized, double-blind, placebo -controlled IIb clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in people 6 years old and…
- Trial name
- NCT04566770
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Alzheimer Disease
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to…
- Trial name
- NCT00297362
- Testing
- Galantamine hydrobromide
- Volunteers
- 344 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Alzheimer's Disease
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per…
- Trial name
- NCT02989402
- Testing
- Rivastigmine
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Dementia, Alzheimer Type
TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
The primary objective of the study is to investigate the effects of oral TRx0014 at three doses (30, 60 and 100 mg tid) compared with placebo on cognitive ability in patients with mild or moderate dementia of the Alzheimer type.
- Trial name
- NCT00515333
- Testing
- TRx0014
- Volunteers
- 323 people
- Sponsor
- TauRx Therapeutics Ltd
Agitation Associated With Alzheimer's Disease, Alzheimer's Type
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
- Conditions
- Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02192554
- Where
- 84 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
COVID-19
A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.
The study is a single-center, randomized and double-blinded trial to evaluate the immunobridging between different manufacture scales, lot-to-lot consistency of the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5…
- Trial name
- NCT04916886
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
- Where
- China
- Volunteers
- 2,021 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.